Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)

Corvus Pharmaceuticals, Inc. CRVS

Healthcare - Biotechnology - NASDAQ - US

Watchlist

$ 8.19

-3.87 %

$ 526 M

Market Cap

-19.98

P/E

1. INTRINSIC VALUE

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer.[ Read More ]

The intrinsic value of one CRVS stock under the base case scenario is HIDDEN Compared to the current market price of 8.19 USD, Corvus Pharmaceuticals, Inc. is HIDDEN

CRVS Intrinsic Value
HIDDEN

SHOW

2. FUNDAMENTAL ANALYSIS

Price Chart CRVS

FINANCIALS

Annual
Quarterly

0 REVENUE

Growth Rates

1Year 0.00%

3Years 0.00%

5Years 0.00%

7Years 0.00%

10Years 0.00%

-23.3 M OPERATING INCOME

Growth Rates

1Year 28.36%

3Years 18.92%

5Years 13.87%

7Years 6.37%

10Years 0.00%

-27 M NET INCOME

Growth Rates

1Year 34.57%

3Years -65.20%

5Years 10.45%

7Years 4.15%

10Years 0.00%

-23.9 M OPERATING CASH FLOW

Growth Rates

1Year 11.43%

3Years 11.71%

5Years 10.20%

7Years 2.14%

10Years 0.00%

15.5 M INVESTING CASH FLOW

Growth Rates

1Year 166.77%

3Years -29.72%

5Years 20.25%

7Years 13.09%

10Years 0.00%

7.86 M FINANCING CASH FLOW

Growth Rates

1Year 0.00%

3Years 81.67%

5Years -34.52%

7Years -27.04%

10Years 0.00%

0 REVENUE

Growth Rates

1Year 0.00%

3Years 0.00%

5Years 0.00%

7Years 0.00%

10Years 0.00%

-7.26 M OPERATING INCOME

Growth Rates

1Year 28.36%

3Years 18.92%

5Years 13.87%

7Years 6.37%

10Years 0.00%

-40.2 M NET INCOME

Growth Rates

1Year 34.57%

3Years -65.20%

5Years 10.45%

7Years 4.15%

10Years 0.00%

-6.32 M OPERATING CASH FLOW

Growth Rates

1Year 11.43%

3Years 11.71%

5Years 10.20%

7Years 2.14%

10Years 0.00%

-3.89 M INVESTING CASH FLOW

Growth Rates

1Year 166.77%

3Years -29.72%

5Years 20.25%

7Years 13.09%

10Years 0.00%

50 K FINANCING CASH FLOW

Growth Rates

1Year 0.00%

3Years 81.67%

5Years -34.52%

7Years -27.04%

10Years 0.00%

Balance Sheet Decomposition Corvus Pharmaceuticals, Inc.

45.6 M ASSETS
6.87 M LIABILITIES

Current Assets	28 M
Cash & Short-Term Investments	27.1 M
Receivables	63 K
Other Current Assets	744 K
Non-Current Assets	17.6 M
Long-Term Investments	16.1 M
PP&E	1.38 M
Other Non-Current Assets	89 K

Current Liabilities	6.87 M
Accounts Payable	1.52 M
Short-Term Debt	2.75 M
Other Current Liabilities	2.6 M
Non-Current Liabilities	0
Long-Term Debt	0
Other Non-Current Liabilities	0

EFFICIENCY

Earnings Waterfall Corvus Pharmaceuticals, Inc.

Revenue	0
Cost Of Revenue	151 K
Gross Profit	-151 K
Operating Expenses	23.4 M
Operating Income	-23.3 M
Other Expenses	3.7 M
Net Income	-27 M

RATIOS

0.00% GROSS MARGIN

Averages

1Year 0.00%

3Years 0.00%

5Years 0.00%

7Years 0.00%

10Years 0.00%

0.00% OPERATING MARGIN

Averages

1Year 0.00%

3Years 0.00%

5Years 0.00%

7Years 0.00%

10Years 0.00%

0.00% NET MARGIN

Averages

1Year 0.00%

3Years 0.00%

5Years 0.00%

7Years 0.00%

10Years 0.00%

-69.87% ROE

Averages

1Year -69.87%

3Years -66.13%

5Years -53.32%

7Years -53.53%

10Years -19.09%

-59.34% ROA

Averages

1Year -59.34%

3Years -55.86%

5Years -45.10%

7Years -46.28%

10Years -38.31%

-58.24% ROIC

Averages

1Year -58.24%

3Years -53.69%

5Years -54.29%

7Years -54.83%

10Years -37.42%

FREE CASH FLOW ANALYSIS

Free Cash Flow Analysis Corvus Pharmaceuticals, Inc.

Net Income	-27 M
Depreciation & Amortization	151 K
Capital Expenditures	-34 K
Stock-Based Compensation	2.15 M
Change in Working Capital	-3.59 M
Others	685 K
Free Cash Flow	-24 M

3. WALL STREET ANALYSTS ESTIMATES

Wall Street Analysts Price Targets Corvus Pharmaceuticals, Inc.

Wall Street analysts predict an average 1-year price target for CRVS of $11.4 , with forecasts ranging from a low of $7 to a high of $13 .

CRVS Lowest Price Target Wall Street Target

7 USD -14.53%

CRVS Average Price Target Wall Street Target

11.4 USD 39.19%

CRVS Highest Price Target Wall Street Target

13 USD 58.73%

4. DIVIDEND ANALYSIS

0.00% DIVIDEND YIELD

0 USD DIVIDEND PER SHARE

5. COMPETITION

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally.

-0.0218 USD

MREO

Overvalued 100.62%

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity.

1.11 USD

TERN

Overvalued 81.96%

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer.

1.06 USD

PDSB

Overvalued 47.42%

Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases.

-0.232 USD

INZY

Overvalued 107.41%

HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform.

3.56 USD

HOOK

Undervalued 18.58%

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases.

0.23 USD

XFOR

Overvalued 42.95%

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma.

2.89 USD

DAWN

Overvalued 78.30%

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers.

0.79 USD

ABOS

Overvalued 67.09%

6. Ownership

Insider Ownership Corvus Pharmaceuticals, Inc.

Summary
Transactions

Sold

0-3 MONTHS

0 USD 0

3-6 MONTHS

0 USD 0

6-9 MONTHS

0 USD 0

9-12 MONTHS

0 USD 0

Bought

0 USD 0

0-3 MONTHS

0 USD 0

3-6 MONTHS

12.8 M USD 4

6-9 MONTHS

0 USD 0

9-12 MONTHS

Date	Value	Insider	Amount	Avg Price
6 months ago May 06, 2024	Bought 144 USD	Thompson Peter A. director, 10 percent owner:	+ 1444085	0.0001 USD
6 months ago May 06, 2024	Bought 4.89 M USD	Thompson Peter A. director, 10 percent owner:	+ 1397684	3.5 USD
6 months ago May 06, 2024	Bought 144 USD	ORBIMED ADVISORS LLC director, 10 percent owner:	+ 1444085	0.0001 USD
6 months ago May 06, 2024	Bought 4.89 M USD	ORBIMED ADVISORS LLC director, 10 percent owner:	+ 1397684	3.5 USD
6 months ago May 06, 2024	Bought 34.6 K USD	Jones William Benton See Remarks	+ 20000	1.7312 USD
6 months ago May 06, 2024	Bought 67.7 K USD	Jones William Benton See Remarks	+ 19357	3.5 USD
6 months ago May 06, 2024	Bought 1 M USD	MILLER RICHARD A MD President and CEO	+ 577634	1.7312 USD
6 months ago May 06, 2024	Bought 1.96 M USD	MILLER RICHARD A MD President and CEO	+ 559073	3.5 USD
1 year ago May 15, 2023	Bought 24.5 K USD	Grais Linda Director	+ 10000	2.45 USD
1 year ago Dec 20, 2022	Bought 15.8 K USD	Jones William Benton See Remarks	+ 20000	0.79 USD
1 year ago Dec 14, 2022	Bought 3.36 K USD	LEA LEIV Chief Financial Officer	+ 4000	0.841 USD
1 year ago Dec 13, 2022	Bought 22.3 K USD	LEA LEIV Chief Financial Officer	+ 30000	0.7425 USD
1 year ago Dec 14, 2022	Bought 7.81 K USD	MILLER RICHARD A MD President and CEO	+ 10000	0.7812 USD
1 year ago Dec 13, 2022	Bought 37 K USD	MILLER RICHARD A MD President and CEO	+ 50000	0.7403 USD
2 years ago Sep 28, 2022	Bought 19.1 K USD	MILLER RICHARD A MD President and CEO	+ 25000	0.7628 USD
2 years ago Sep 20, 2022	Bought 4.07 K USD	MILLER RICHARD A MD President and CEO	+ 5000	0.815 USD
2 years ago Sep 20, 2022	Bought 2.21 K USD	MILLER RICHARD A MD President and CEO	+ 2700	0.82 USD
2 years ago Sep 20, 2022	Bought 9.96 K USD	MILLER RICHARD A MD President and CEO	+ 12300	0.8101 USD
2 years ago Jun 24, 2022	Bought 4.98 K USD	MILLER RICHARD A MD President and CEO	+ 5000	0.9969 USD
2 years ago Jun 24, 2022	Bought 5.15 K USD	MILLER RICHARD A MD President and CEO	+ 5000	1.03 USD
2 years ago Jun 02, 2022	Bought 899 USD	MILLER RICHARD A MD President and CEO	+ 890	1.01 USD
2 years ago Jun 02, 2022	Bought 165 USD	MILLER RICHARD A MD President and CEO	+ 170	0.97 USD
2 years ago Jun 02, 2022	Bought 4.73 K USD	MILLER RICHARD A MD President and CEO	+ 4830	0.98 USD
2 years ago Mar 31, 2022	Bought 24.5 K USD	MILLER RICHARD A MD President and CEO	+ 15000	1.6356 USD
2 years ago Mar 16, 2022	Bought 22.9 K USD	LEA LEIV Chief Financial Officer	+ 13878	1.65 USD
2 years ago Mar 15, 2022	Bought 7.95 K USD	MILLER RICHARD A MD President and CEO	+ 5000	1.59 USD
2 years ago Mar 15, 2022	Bought 36.6 K USD	MILLER RICHARD A MD President and CEO	+ 25000	1.466 USD
3 years ago Sep 30, 2021	Sell 15.1 M USD	EcoR1 Capital, LLC 10 percent owner	- 3000000	5.0437 USD
3 years ago Oct 01, 2021	Sell 9.93 M USD	EcoR1 Capital, LLC 10 percent owner	- 2000000	4.9644 USD
3 years ago Sep 20, 2021	Sell 6.76 M USD	ORBIMED ADVISORS LLC director, 10 percent owner:	- 1109644	6.09 USD
3 years ago Sep 20, 2021	Sell 6.76 M USD	Thompson Peter A. director, 10 percent owner:	- 1109644	6.09 USD
3 years ago Aug 20, 2021	Bought 19.3 K USD	MILLER RICHARD A MD President and CEO	+ 10000	1.9254 USD
3 years ago May 04, 2021	Bought 100 K USD	MILLER RICHARD A MD President and CEO	+ 35714	2.8 USD
3 years ago Feb 17, 2021	Bought 4.5 M USD	ORBIMED ADVISORS LLC director, 10 percent owner:	+ 1285714	3.5 USD
3 years ago Feb 17, 2021	Bought 4.5 M USD	Thompson Peter A. director, 10 percent owner:	+ 1285714	3.5 USD
3 years ago Feb 17, 2021	Bought 350 K USD	MILLER RICHARD A MD President and CEO	+ 100000	3.5 USD
4 years ago Jul 07, 2020	Sell 4.18 M USD	Novo Holdings A/S 10 percent owner	- 796622	5.2514 USD
4 years ago Jul 08, 2020	Sell 3.99 M USD	Novo Holdings A/S 10 percent owner	- 741440	5.3749 USD
5 years ago Nov 13, 2019	Bought 44.2 K USD	MILLER RICHARD A MD President and CEO	+ 14736	3.0022 USD
5 years ago Nov 12, 2019	Bought 789 USD	MILLER RICHARD A MD President and CEO	+ 272	2.9 USD
5 years ago Aug 06, 2019	Bought 501 K USD	Thompson Peter A. director, 10 percent owner:	+ 142656	3.51 USD
5 years ago Aug 06, 2019	Bought 501 K USD	ORBIMED ADVISORS LLC director, 10 percent owner:	+ 142656	3.51 USD
5 years ago Aug 07, 2019	Bought 8.85 K USD	MILLER RICHARD A MD President and CEO	+ 2500	3.54 USD
5 years ago Aug 06, 2019	Bought 17.9 K USD	MILLER RICHARD A MD President and CEO	+ 5000	3.575 USD
5 years ago Jul 23, 2019	Sell 211 K USD	Novo Holdings A/S 10 percent owner	- 39716	5.3161 USD
5 years ago Jul 24, 2019	Sell 267 K USD	Novo Holdings A/S 10 percent owner	- 53240	5.0096 USD
5 years ago Jul 25, 2019	Sell 5.6 M USD	Novo Holdings A/S 10 percent owner	- 1400000	4 USD
5 years ago Jul 01, 2019	Bought 232 K USD	Thompson Peter A. director, 10 percent owner:	+ 59243	3.91 USD
5 years ago Jun 28, 2019	Bought 2.1 M USD	Thompson Peter A. director, 10 percent owner:	+ 565178	3.72 USD
5 years ago Jun 27, 2019	Bought 110 K USD	Thompson Peter A. director, 10 percent owner:	+ 32923	3.34 USD
5 years ago Jul 01, 2019	Bought 232 K USD	ORBIMED ADVISORS LLC director, 10 percent owner:	+ 59243	3.91 USD
5 years ago Jun 28, 2019	Bought 2.1 M USD	ORBIMED ADVISORS LLC director, 10 percent owner:	+ 565178	3.72 USD
5 years ago Jun 27, 2019	Bought 110 K USD	ORBIMED ADVISORS LLC director, 10 percent owner:	+ 32923	3.34 USD
5 years ago Jun 14, 2019	Bought 39.7 K USD	MILLER RICHARD A MD President and CEO	+ 11657	3.4028 USD
5 years ago Jun 13, 2019	Bought 1.21 K USD	MILLER RICHARD A MD President and CEO	+ 343	3.52 USD
5 years ago Jun 11, 2019	Bought 22 K USD	MILLER RICHARD A MD President and CEO	+ 6000	3.67 USD
5 years ago Jun 07, 2019	Bought 31 K USD	MILLER RICHARD A MD President and CEO	+ 9212	3.3672 USD
5 years ago Jun 07, 2019	Bought 33.8 K USD	LEA LEIV Chief Financial Officer	+ 10000	3.38 USD
5 years ago Jun 06, 2019	Bought 55.2 K USD	LEA LEIV Chief Financial Officer	+ 15500	3.56 USD
5 years ago Dec 27, 2018	Bought 65.9 K USD	MILLER RICHARD A MD President and CEO	+ 20000	3.2942 USD
5 years ago Dec 21, 2018	Bought 102 K USD	LEA LEIV Chief Financial Officer	+ 24700	4.1461 USD
5 years ago Dec 20, 2018	Bought 22 K USD	MILLER RICHARD A MD President and CEO	+ 5000	4.39 USD
5 years ago Dec 20, 2018	Bought 22 K USD	MILLER RICHARD A MD President and CEO	+ 5000	4.4 USD
5 years ago Dec 06, 2018	Bought 29.9 K USD	MILLER RICHARD A MD President and CEO	+ 5000	5.9868 USD
5 years ago Dec 04, 2018	Bought 8.94 K USD	MILLER RICHARD A MD President and CEO	+ 1502	5.95 USD
6 years ago Mar 12, 2018	Bought 5 M USD	Thompson Peter A. director, 10 percent owner:	+ 588235	8.5 USD
6 years ago Mar 12, 2018	Bought 5 M USD	ORBIMED ADVISORS LLC director, 10 percent owner:	+ 588235	8.5 USD
6 years ago Mar 12, 2018	Bought 10 M USD	Novo Holdings A/S 10 percent owner	+ 1176470	8.5 USD
6 years ago Mar 12, 2018	Bought 2.01 M USD	Gould Terry P director, 10 percent owner:	+ 236128	8.5 USD
6 years ago Mar 12, 2018	Bought 1.08 M USD	Gould Terry P director, 10 percent owner:	+ 126806	8.5 USD
6 years ago Mar 12, 2018	Bought 745 K USD	Gould Terry P director, 10 percent owner:	+ 87668	8.5 USD
6 years ago Mar 12, 2018	Bought 594 K USD	Gould Terry P director, 10 percent owner:	+ 69864	8.5 USD
6 years ago Mar 12, 2018	Bought 576 K USD	Gould Terry P director, 10 percent owner:	+ 67769	8.5 USD
6 years ago Mar 12, 2018	Bought 2.01 M USD	ADAMS STREET PARTNERS LLC 10 percent owner	+ 236128	8.5 USD
6 years ago Mar 12, 2018	Bought 1.08 M USD	ADAMS STREET PARTNERS LLC 10 percent owner	+ 126806	8.5 USD
6 years ago Mar 12, 2018	Bought 745 K USD	ADAMS STREET PARTNERS LLC 10 percent owner	+ 87668	8.5 USD
6 years ago Mar 12, 2018	Bought 594 K USD	ADAMS STREET PARTNERS LLC 10 percent owner	+ 69864	8.5 USD
6 years ago Mar 12, 2018	Bought 576 K USD	ADAMS STREET PARTNERS LLC 10 percent owner	+ 67769	8.5 USD
6 years ago Mar 12, 2018	Bought 850 K USD	MILLER RICHARD A MD President and CEO	+ 100000	8.5 USD
6 years ago Nov 20, 2017	Bought 108 K USD	MILLER RICHARD A MD President and CEO	+ 10000	10.785 USD
7 years ago Jun 23, 2017	Bought 219 K USD	Novo Holdings A/S 10 percent owner	+ 20000	10.95 USD
7 years ago Jun 13, 2017	Bought 25.4 K USD	MILLER RICHARD A MD President and CEO	+ 2500	10.14 USD
7 years ago Jun 13, 2017	Bought 24.4 K USD	MILLER RICHARD A MD President and CEO	+ 2500	9.75 USD
7 years ago Jun 12, 2017	Bought 110 K USD	MILLER RICHARD A MD President and CEO	+ 11216	9.8239 USD
7 years ago Jun 09, 2017	Bought 37.4 K USD	MILLER RICHARD A MD President and CEO	+ 3784	9.89 USD
7 years ago Jun 09, 2017	Bought 49.8 K USD	MILLER RICHARD A MD President and CEO	+ 5000	9.95 USD
8 years ago Jun 24, 2016	Bought 11.7 K USD	Thompson Peter A. director, 10 percent owner:	+ 900	12.99 USD
8 years ago Jun 23, 2016	Bought 1.29 K USD	Thompson Peter A. director, 10 percent owner:	+ 100	12.92 USD
8 years ago Jun 24, 2016	Bought 11.7 K USD	ORBIMED ADVISORS LLC director, 10 percent owner:	+ 900	12.99 USD
8 years ago Jun 23, 2016	Bought 1.29 K USD	ORBIMED ADVISORS LLC director, 10 percent owner:	+ 100	12.92 USD
8 years ago Jun 21, 2016	Bought 336 K USD	Thompson Peter A. director, 10 percent owner:	+ 26083	12.87 USD
8 years ago Jun 17, 2016	Bought 154 K USD	Thompson Peter A. director, 10 percent owner:	+ 12300	12.48 USD
8 years ago Jun 21, 2016	Bought 336 K USD	ORBIMED ADVISORS LLC director, 10 percent owner:	+ 26083	12.87 USD
8 years ago Jun 17, 2016	Bought 154 K USD	ORBIMED ADVISORS LLC director, 10 percent owner:	+ 12300	12.48 USD
8 years ago Jun 16, 2016	Bought 60.2 K USD	Thompson Peter A. director, 10 percent owner:	+ 5000	12.04 USD
8 years ago Jun 15, 2016	Bought 59.7 K USD	Thompson Peter A. director, 10 percent owner:	+ 5000	11.94 USD
8 years ago Jun 14, 2016	Bought 127 K USD	Thompson Peter A. director, 10 percent owner:	+ 10000	12.71 USD
8 years ago Jun 16, 2016	Bought 60.2 K USD	ORBIMED ADVISORS LLC director, 10 percent owner:	+ 5000	12.04 USD
8 years ago Jun 15, 2016	Bought 59.7 K USD	ORBIMED ADVISORS LLC director, 10 percent owner:	+ 5000	11.94 USD
8 years ago Jun 14, 2016	Bought 127 K USD	ORBIMED ADVISORS LLC director, 10 percent owner:	+ 10000	12.71 USD
8 years ago Jun 10, 2016	Bought 260 K USD	Thompson Peter A. director, 10 percent owner:	+ 20000	12.98 USD
8 years ago Jun 09, 2016	Bought 388 K USD	Thompson Peter A. director, 10 percent owner:	+ 30000	12.95 USD
8 years ago Jun 10, 2016	Bought 260 K USD	ORBIMED ADVISORS LLC director, 10 percent owner:	+ 20000	12.98 USD
8 years ago Jun 09, 2016	Bought 388 K USD	ORBIMED ADVISORS LLC director, 10 percent owner:	+ 30000	12.95 USD
8 years ago May 20, 2016	Bought 61.7 K USD	Thompson Peter A. director, 10 percent owner:	+ 4716	13.09 USD
8 years ago May 20, 2016	Bought 61.7 K USD	ORBIMED ADVISORS LLC director, 10 percent owner:	+ 4716	13.09 USD
8 years ago May 19, 2016	Bought 778 USD	ORBIMED ADVISORS LLC Director	+ 61	12.75 USD
8 years ago May 19, 2016	Bought 30.7 K USD	ORBIMED ADVISORS LLC Director	+ 2539	12.11 USD
8 years ago May 18, 2016	Bought 48.5 K USD	ORBIMED ADVISORS LLC Director	+ 4200	11.55 USD
8 years ago May 19, 2016	Bought 778 USD	Thompson Peter A. director, 10 percent owner:	+ 61	12.75 USD
8 years ago May 19, 2016	Bought 30.7 K USD	Thompson Peter A. director, 10 percent owner:	+ 2539	12.11 USD
8 years ago May 18, 2016	Bought 48.5 K USD	Thompson Peter A. director, 10 percent owner:	+ 4200	11.55 USD
8 years ago May 13, 2016	Bought 2.98 K USD	MILLER RICHARD A MD President and CEO	+ 300	9.9367 USD
8 years ago May 12, 2016	Bought 300 K USD	MILLER RICHARD A MD President and CEO	+ 30000	10 USD
8 years ago May 12, 2016	Bought 700 K USD	Novo A/S 10 percent owner	+ 70000	10 USD
8 years ago Mar 29, 2016	Bought 10 M USD	Novo A/S 10 percent owner	+ 666666	15 USD
8 years ago Mar 29, 2016	Bought 8.25 M USD	ORBIMED ADVISORS LLC director, 10 percent owner:	+ 550000	15 USD
8 years ago Mar 29, 2016	Bought 8.25 M USD	Thompson Peter A. director, 10 percent owner:	+ 550000	15 USD
8 years ago Mar 29, 2016	Bought 822 K USD	ADAMS STREET PARTNERS LLC 10 percent owner	+ 54777	15 USD
8 years ago Mar 29, 2016	Bought 799 K USD	ADAMS STREET PARTNERS LLC 10 percent owner	+ 53239	15 USD
8 years ago Mar 29, 2016	Bought 776 K USD	ADAMS STREET PARTNERS LLC 10 percent owner	+ 51712	15 USD
8 years ago Mar 29, 2016	Bought 604 K USD	ADAMS STREET PARTNERS LLC 10 percent owner	+ 40272	15 USD
8 years ago Mar 29, 2016	Bought 822 K USD	Gould Terry P director, 10 percent owner:	+ 54777	15 USD
8 years ago Mar 29, 2016	Bought 799 K USD	Gould Terry P director, 10 percent owner:	+ 53239	15 USD
8 years ago Mar 29, 2016	Bought 776 K USD	Gould Terry P director, 10 percent owner:	+ 51712	15 USD
8 years ago Mar 29, 2016	Bought 604 K USD	Gould Terry P director, 10 percent owner:	+ 40272	15 USD

7. News

Corvus (CRVS) is on the Move, Here's Why the Trend Could be Sustainable Corvus (CRVS) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move. zacks.com - 1 day ago

Corvus Pharmaceuticals Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic Sclerosis Adds to growing body of evidence supporting the potential of ITK inhibition as a novel therapeutic for the treatment of a wide range of immune diseases globenewswire.com - 2 days ago

Corvus Pharmaceuticals: The Market Likes The Story Today, we take a look at Corvus Pharmaceuticals, whose stock has rocketed from under $2 a share this summer to around ten bucks a share. The company is advancing a couple of intriguing candidates within its developmental pipeline and recently kicked of a pivotal Phase 3 registrational study. Can the rally continue as the market increasingly buys into the story around Corvus or is some profit taking on the horizon? seekingalpha.com - 3 days ago

Corvus Pharmaceuticals, Inc. (CRVS) Q3 2024 Earnings Call Transcript Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Zack Kubow - Real Chemistry, IR Leiv Lea - Chief Financial Officer Richard Miller - Chief Executive Officer Conference Call Participants Li Watsek - Cantor Jiale Song - Jefferies Aydin Huseynov - Ladenburg Graig Suvannavejh - Mizuho Jeff Jones - Oppenheimer Operator Good afternoon, everyone, and thank you for standing by, and welcome to the Corvus Pharmaceuticals Third Quarter 2024 Business Update and Financial Results Conference Call. At this time participants are in a listen-only mode. seekingalpha.com - 4 days ago

Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results Soquelitinib Atopic Dermatitis Phase 1 Clinical Trial Enrolling Patients in Second Dosing Cohort Interim Data from Atopic Dermatitis Trial Expected to be Announced December 2024 Registration Phase 3 Clinical Trial of Soquelitinib in Peripheral T Cell Lymphoma (PTCL) Enrolling with Multiple Clinical Sites Open Conference call today at 4:30 p.m. ET / 1:30 p.m. globenewswire.com - 4 days ago

Corvus Pharmaceuticals Announces New Data Highlighting Potential of Ciforadenant to Overcome Immunotherapy Resistance in Metastatic Castration Resistant Prostate Cancer Data presented in an oral session at the Society for Immunotherapy of Cancer 39th Annual Meeting, where it was selected as a top 100 abstract Data presented in an oral session at the Society for Immunotherapy of Cancer 39th Annual Meeting, where it was selected as a top 100 abstract globenewswire.com - 1 week ago

Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2024 Financial Results on November 12, 2024 Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT globenewswire.com - 1 week ago

Corvus Stock Up on Initiation of Phase III Lymphoma Study on Lead Drug CRVS stock gains 14% on initiating a registrational study on its lead candidate, soquelitinib, to treat relapsed/refractory peripheral T-cell lymphoma. zacks.com - 2 months ago

Corvus Pharmaceuticals Initiates Registrational Phase 3 Clinical Trial of Soquelitinib for Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma Soquelitinib is a potential first-in-class ITK inhibitor with broad potential in cancer and immune diseases There are currently no fully approved agents for the treatment of relapsed PTCL and soquelitinib has been granted Orphan Drug Designation and Fast Track Designation by the FDA BURLINGAME, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it has initiated a registrational Phase 3 clinical trial of soquelitinib for patients with relapsed/refractory peripheral T-cell lymphoma (PTCL). globenewswire.com - 2 months ago

Corvus Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference BURLINGAME, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that Richard A. Miller, M.D., president and chief executive officer, and Jeffrey Arcara, chief business officer, will conduct one-on-one meetings with investors and present a corporate overview at the H.C. Wainwright 26th Annual Global Investment Conference, which is being held in New York from September 9-11, 2024. The Company's presentation will be on Tuesday, September 10 at 12:00pm ET. globenewswire.com - 2 months ago

Corvus Pharmaceuticals Eyes Phase 3 Trials: Soquelitinib's Promise In PTCL Corvus Pharmaceuticals' lead candidate, Soquelitinib, is advancing towards a Phase 3 trial for PTCL, set to begin in September 2024. Soquelitinib has shown a 26% Complete Response Rate [CRR] in early trials, more than double the current standard of care. The PTCL market, estimated at $500 million in the U.S., offers significant potential if Soquelitinib's Phase 3 trials are successful. seekingalpha.com - 2 months ago

Corvus Pharmaceuticals, Inc. (CRVS) Q2 2024 Earnings Call Transcript Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS ) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Zack Kubow - Real Chemistry, IR Richard Miller - Chief Executive Officer Leiv Lea - Chief Financial Officer Jeff Arcara - Chief Business Officer Jim Rosenbaum - Senior Vice President, Research Ben Jones - Senior Vice President, Regulatory and Pharmaceutical Sciences Conference Call Participants Li Watsek - Cantor Roger Song - Jefferies Aydin Huseynov - Ladenberg Jeff Jones - Oppenheimer Graig Suvannavejh - Mizuho Operator Good afternoon, everyone, and thank you for standing by. Welcome to the Corvus Pharmaceuticals Second Quarter 2024 Business Update and Financial Results Conference Call. seekingalpha.com - 3 months ago

8. Profile Summary

Corvus Pharmaceuticals, Inc. CRVS

COUNTRY US

INDUSTRY Biotechnology

MARKET CAP $ 526 M

Dividend Yield 0.00%

Description Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.

Contact 863 Mitten Road, Burlingame, CA, 94010 https://www.corvuspharma.com

IPO Date March 23, 2016

Employees 28

Officers Mr. Jeffrey S. Arcara Chief Business Officer Dr. Richard A. Miller M.D. Co-Founder, President, Chief Executive Officer & Chairman of the Board Dr. William Benton Jones Ph.D. Senior Vice President of Pharmaceutical Development Dr. Peter A. Thompson FACP, M.D. Co-Founder & Independent Director Mr. Leiv Lea Chief Financial Officer Dr. James T. Rosenbaum M.D. Senior Vice President of Research

Price Chart CRVS

Corvus Pharmaceuticals, Inc. CRVS

Premium Plan

Unlimited Plan